Cargando…

Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement

A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings, triple therapy with a serotonin (5-hydroxytr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Alexandre, Abdullah, Matin M., Ishak, Wan Zamaniah B. Wan, Ong-Cornel, Annielyn B., Villalon, Antonio H., Kanesvaran, Ravindran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735961/
https://www.ncbi.nlm.nih.gov/pubmed/29244998
http://dx.doi.org/10.1200/JGO.2016.005728
_version_ 1783287303658012672
author Chan, Alexandre
Abdullah, Matin M.
Ishak, Wan Zamaniah B. Wan
Ong-Cornel, Annielyn B.
Villalon, Antonio H.
Kanesvaran, Ravindran
author_facet Chan, Alexandre
Abdullah, Matin M.
Ishak, Wan Zamaniah B. Wan
Ong-Cornel, Annielyn B.
Villalon, Antonio H.
Kanesvaran, Ravindran
author_sort Chan, Alexandre
collection PubMed
description A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings, triple therapy with a serotonin (5-hydroxytryptamine-3 [5-HT(3)]) antagonist (preferably palonosetron), dexamethasone, and aprepitant is recommended for acute CINV prevention. In resource-restricted settings, triple therapy is still recommended, although a 5-HT(3) antagonist other than palonosetron may be used. In both general and resource-restricted settings, dual therapy with dexamethasone (days 2 to 4) and aprepitant (days 2 to 3) is recommended to prevent delayed CINV. In patients treated with moderately emetogenic chemotherapy, dual therapy with a 5-HT(3) antagonist, preferably palonosetron, and dexamethasone is recommended for acute CINV prevention in general settings; any 5-HT(3) antagonist can be combined with dexamethasone in resource-restricted environments. In general settings, for the prevention of delayed CINV associated with moderately emetogenic chemotherapy, corticosteroid monotherapy on days 2 and 3 is recommended. If aprepitant is used on day 1, it should be continued on days 2 and 3. Prevention of delayed CINV with corticosteroids is preferred in resource-restricted settings. The expert panel also developed CINV management guidelines for anthracycline plus cyclophosphamide combination schedules, multiday cisplatin, and chemotherapy with low or minimal emetogenic potential, and its recommendations are detailed in this review. Overall, these regional guidelines provide definitive guidance for CINV management in general and resource-restricted settings. These consensus recommendations are anticipated to contribute to collaborative efforts to improve CINV management in Southeast Asia.
format Online
Article
Text
id pubmed-5735961
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-57359612018-01-03 Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement Chan, Alexandre Abdullah, Matin M. Ishak, Wan Zamaniah B. Wan Ong-Cornel, Annielyn B. Villalon, Antonio H. Kanesvaran, Ravindran J Glob Oncol Special Articles A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings, triple therapy with a serotonin (5-hydroxytryptamine-3 [5-HT(3)]) antagonist (preferably palonosetron), dexamethasone, and aprepitant is recommended for acute CINV prevention. In resource-restricted settings, triple therapy is still recommended, although a 5-HT(3) antagonist other than palonosetron may be used. In both general and resource-restricted settings, dual therapy with dexamethasone (days 2 to 4) and aprepitant (days 2 to 3) is recommended to prevent delayed CINV. In patients treated with moderately emetogenic chemotherapy, dual therapy with a 5-HT(3) antagonist, preferably palonosetron, and dexamethasone is recommended for acute CINV prevention in general settings; any 5-HT(3) antagonist can be combined with dexamethasone in resource-restricted environments. In general settings, for the prevention of delayed CINV associated with moderately emetogenic chemotherapy, corticosteroid monotherapy on days 2 and 3 is recommended. If aprepitant is used on day 1, it should be continued on days 2 and 3. Prevention of delayed CINV with corticosteroids is preferred in resource-restricted settings. The expert panel also developed CINV management guidelines for anthracycline plus cyclophosphamide combination schedules, multiday cisplatin, and chemotherapy with low or minimal emetogenic potential, and its recommendations are detailed in this review. Overall, these regional guidelines provide definitive guidance for CINV management in general and resource-restricted settings. These consensus recommendations are anticipated to contribute to collaborative efforts to improve CINV management in Southeast Asia. American Society of Clinical Oncology 2016-11-09 /pmc/articles/PMC5735961/ /pubmed/29244998 http://dx.doi.org/10.1200/JGO.2016.005728 Text en © 2016 by American Society of Clinical Oncology http://creativecommons.org/licenses/by-nc-nd/4.0/ Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Special Articles
Chan, Alexandre
Abdullah, Matin M.
Ishak, Wan Zamaniah B. Wan
Ong-Cornel, Annielyn B.
Villalon, Antonio H.
Kanesvaran, Ravindran
Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement
title Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement
title_full Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement
title_fullStr Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement
title_full_unstemmed Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement
title_short Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement
title_sort applicability of the national comprehensive cancer network/multinational association of supportive care in cancer guidelines for prevention and management of chemotherapy-induced nausea and vomiting in southeast asia: a consensus statement
topic Special Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735961/
https://www.ncbi.nlm.nih.gov/pubmed/29244998
http://dx.doi.org/10.1200/JGO.2016.005728
work_keys_str_mv AT chanalexandre applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement
AT abdullahmatinm applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement
AT ishakwanzamaniahbwan applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement
AT ongcornelannielynb applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement
AT villalonantonioh applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement
AT kanesvaranravindran applicabilityofthenationalcomprehensivecancernetworkmultinationalassociationofsupportivecareincancerguidelinesforpreventionandmanagementofchemotherapyinducednauseaandvomitinginsoutheastasiaaconsensusstatement